AQST Earnings Prediction
The chart below shows how AQST performed 10 days before and after its earnings report, based on data from the past quarters. Typically, AQST sees a -4.85% change in stock price 10 days leading up to the earnings, and a +10.38% change 10 days following the report. On the earnings day itself, the stock moves by -0.04%. This data can give you a slight idea of what to expect for the next quarter's release.
AQST Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
11.87M
-10.14%
-12.37%
Gross Margin
61.91%
-4.12%
-7.93%
Operating Margin
-114.43%
286.33%
86.92%
Net Margin
-143.72%
134.00%
69.10%
EPS
-0.19
-58.33%
46.15%
No Data Available
AQST Earnings Analysis
Aquestive Therapeutics Inc Corporation (AQST.O) Earnings Conference Call
Positive
FDA Filing for Anaphylm: The company has begun the filing process with the FDA for Anaphylm, with expectations for NDA acceptance in June 2025 and a potential launch in Q1 2026.
Pediatric Study Progress Update: The pediatric study for Anaphylm is progressing as expected, with data to support the product label mirroring existing EpiPen parameters.
Physician Awareness and Preferences: A recent awareness trial showed that 92% of physicians are aware of the new nasal spray product, and sublingual film was preferred over auto-injectors and nasal sprays in theoretical prescribing habits.
Anaphylm Launch Preparation: The company is preparing for the commercial launch of Anaphylm, including hiring in-house market access expertise and increasing medical publications and conference presence.
International Market Expansion Plans: Plans for international market submissions for Anaphylm in the EU, UK, and Canada are underway, with potential partnerships for ex-U.S. commercialization.
IND Submission for AQST-108: The company is set to open an IND for AQST-108, a topical gel formulation of epinephrine, with a Phase 2a trial expected to start in the next quarter.
Capital Raise for Investments: The company raised over $78 million in capital from institutional investors, strengthening its balance sheet for strategic investments.
2025 Revenue Outlook: The outlook for 2025 includes total revenues of approximately $47 million to $56 million, indicating growth potential despite some revenue erosion in Suboxone.
Negative
Revenue Decline Analysis: Total revenue decreased to $11.9 million in Q4 2024 from $13.2 million in Q4 2023, a 10% decrease primarily driven by decreases in license and royalty revenue.
Revenue Decline Analysis: Manufacture and supply revenue decreased to $10.7 million in Q4 2024 from $11 million in Q4 2023, primarily due to a decrease in Suboxone revenues.
Royalty Revenue Decline: License and royalty revenue decreased to $0.8 million in Q4 2024 from $1.9 million in Q4 2023, primarily due to a prior year milestone royalty revenue for Azstarys.
Increased Net Loss: Net loss for Q4 2024 was $17.1 million, compared to a net loss of $8.1 million in Q4 2023, indicating a significant increase in losses.
Increased Net Loss: Net loss for the full year 2024 was $44.1 million, compared to $7.9 million in 2023, reflecting a substantial increase in overall losses.
EBITDA Loss Comparison: Non-GAAP adjusted EBITDA loss was $11 million in Q4 2024, compared to a loss of $2.8 million in Q4 2023, indicating worsening financial performance.
SG&A Expense Increase: Selling, general and administrative expenses increased to $16 million in Q4 2024 from $9.6 million in Q4 2023, driven by increased commercial spending and severance costs.
R&D Expense Increase: Research and development expenses increased to $4.9 million in Q4 2024 from $2.9 million in Q4 2023, primarily due to clinical trial costs for Anaphylm.
Revenue Forecast for 2025: The company expects total revenues for 2025 to be approximately $47 million to $56 million, which includes anticipated erosion in demand for Suboxone.
AQST FAQs
How does AQST typically perform around its earnings report dates?
Is Aquestive Therapeutics Inc (AQST) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
AQST Earning Call Sentiment
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2024 Earnings Call Transcript
AQST.O
5.3%Positive
The earnings call reveals a mixed financial performance with increased revenue but significant losses and expenses, particularly in R&D and SG&A. The Q&A section highlights uncertainties, such as potential partnership for Anaphylm and Libervant's legal risks. While there is optimism about Anaphylm's launch, the negative financial metrics and unclear management responses overshadow positive aspects. The lack of guidance changes and increased expenses contribute to a negative sentiment, suggesting a potential stock price decline of -2% to -8% over the next two weeks.
